Literature DB >> 21537908

Seizure management in the setting of hepatic disease.

Jane G Boggs1.   

Abstract

OPINION STATEMENT: In the past 20 years, many antiepileptic drugs (AEDs) have been marketed that are not significantly metabolized by the liver, but some patients still require the use of older and more metabolically complex AEDs for optimal seizure control, and current economic and insurance-coverage limitations have forced many patients to switch to less expensive agents, which are often the older AEDs. For the patient with hepatic disease, it is clearly preferable to use medications with little potential to exacerbate their condition. In my practice, I try to use agents with simpler metabolism, especially for patients with multiple medical problems. Doing this can mean using AEDs in monotherapy that are FDA-approved only for adjunctive use. I also find that older agents and hepatically metabolized AEDs can be the most appropriate for particular patients. Selection of the optimal seizure medication requires consideration of multiple factors, only one of which is the impact on liver function. I routinely obtain an executive laboratory panel at least yearly for even the healthiest of patients, to reassure both the patient and myself that the metabolism of their AED regimen is not significantly affected. Occasionally, a change or abnormality in liver function is identified. Certainly hepatic disease can make epilepsy management more difficult, and communication between the neurologist and the other treating physicians is a necessity, although the neurologist and the hepatologist may have differing opinions on how to respond to worsening liver function. Concern about potential liver damage by AEDs may prompt unnecessary discontinuation, sometimes with disastrous consequences for seizure control. Overly complex AED regimens can cause underlying liver problems to worsen. Clinical observation and judgment must complement the data derived from laboratory parameters. Worsening hepatic disease can also result in encephalopathic states that worsen or mimic seizures. The EEG can often be helpful in differentiating these conditions and is crucial in determining appropriate epilepsy therapy.

Entities:  

Year:  2011        PMID: 21537908     DOI: 10.1007/s11940-011-0129-6

Source DB:  PubMed          Journal:  Curr Treat Options Neurol        ISSN: 1092-8480            Impact factor:   3.598


  21 in total

Review 1.  Pharmacogenetics of cytochrome P450 and its applications in drug therapy: the past, present and future.

Authors:  Magnus Ingelman-Sundberg
Journal:  Trends Pharmacol Sci       Date:  2004-04       Impact factor: 14.819

2.  The effect of age upon liver volume and apparent liver blood flow in healthy man.

Authors:  H A Wynne; L H Cope; E Mutch; M D Rawlins; K W Woodhouse; O F James
Journal:  Hepatology       Date:  1989-02       Impact factor: 17.425

3.  Felbamate: 1997 update.

Authors:  J M Pellock; M J Brodie
Journal:  Epilepsia       Date:  1997-12       Impact factor: 5.864

4.  Characteristics of a unique visual field defect attributed to vigabatrin.

Authors:  J M Wild; C Martinez; G Reinshagen; G F Harding
Journal:  Epilepsia       Date:  1999-12       Impact factor: 5.864

Review 5.  Optimizing therapy of seizures in patients with renal or hepatic dysfunction.

Authors:  Glenda Lacerda; Thierry Krummel; Cécile Sabourdy; Philippe Ryvlin; Edouard Hirsch
Journal:  Neurology       Date:  2006-12-26       Impact factor: 9.910

Review 6.  Use of antiepileptic drugs in the presence of liver and kidney diseases: a review.

Authors:  J J Asconapé; J K Penry
Journal:  Epilepsia       Date:  1982       Impact factor: 5.864

7.  Genetic predictors of the maximum doses patients receive during clinical use of the anti-epileptic drugs carbamazepine and phenytoin.

Authors:  Sarah K Tate; Chantal Depondt; Sanjay M Sisodiya; Gianpiero L Cavalleri; Stephanie Schorge; Nicole Soranzo; Maria Thom; Arjune Sen; Simon D Shorvon; Josemir W Sander; Nicholas W Wood; David B Goldstein
Journal:  Proc Natl Acad Sci U S A       Date:  2005-04-01       Impact factor: 11.205

8.  Progress report on new antiepileptic drugs: a summary of the fourth Eilat conference (EILAT IV).

Authors:  M Bialer; S I Johannessen; H J Kupferberg; R H Levy; P Loiseau; E Perucca
Journal:  Epilepsy Res       Date:  1999-03       Impact factor: 3.045

9.  Dress syndrome and fulminant hepatic failure induced by lamotrigine.

Authors:  Marcelo Fabián Amante; Analía Verónica Filippini; Nora Cejas; Javier Lendoire; Oscar Imventarza; Coloma Parisi
Journal:  Ann Hepatol       Date:  2009 Jan-Mar       Impact factor: 2.400

10.  Complications of the ketogenic diet.

Authors:  K Ballaban-Gil; C Callahan; C O'Dell; M Pappo; S Moshé; S Shinnar
Journal:  Epilepsia       Date:  1998-07       Impact factor: 5.864

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.